SUMMARY -We investigated concentrations and roles of insulin-like growth factor 1 (IGF-1) and its binding protein (IGF1BP-3), growth hormone (GH), insulin, and markers of insulin resistance and infl ammation in acute myocardial infarction (AMI). We aimed to assess any possible association between serum GH/IGF-1 axis following AMI and short-term survival rates. A follow up study was performed in 2010. Study group consisted of 75 patients with Killip I and II class AMI. Th ere were 30 control subjects. Blood samples were obtained within 24 hours of admission and analyzed for the aforementioned hormones. Patients were followed-up during 6 months for new cardiac events. Median GH was higher in AMI (0.96; range 0.6-2.4) than in controls (0.26; p<0.001). IGF-1 was signifi cantly lower in AMI (123 vs. 132; p<0.05), and so was the IGF-1/GH ratio (p<0.001) and IGF1BP-3. Insulin was higher in study group, but without statistical signifi cance. However, we found signifi cant between-group diff erences in other markers of insulin resistance (HbA1c, glycemia, HOMA-IR) and infl ammation. Simple linear correlation showed positive correlation between GH and C-reactive protein. All patients with new cardiac events had IGF-1 below median and lower left ventricular ejection fraction. In conclusion, IGF-1 may aff ect outcome of AMI. GH resistance might be a result of infl ammatory/immune response and therefore it could be a useful prognostic marker.
Introduction
Th ere is a complex interplay of insulin-like growth factor 1 (IGF-1), growth hormone (GH) and markers of insulin resistance and infl ammation in acute myocardial infarction (AMI), thus making the story of AMI diffi cult to understand. Whether the GH/IGF-1 axis exerts cardioprotective eff ects remains controversial and the underlying mechanism(s) for such actions are unclear 1 . Basic science reports have emphasized a fundamental role of IGF-1 in regulating myocardial structure and function through its benefi cial eff ects on cardiac myocyte survival, growth, calcium signaling and diff erentiation 1, 2 . In short, the GH-IGF-1 axis includes the hypothalamic-pituitary axis (responsible for the production of GH), GH receptors (responsible for IGF production), IGF binding proteins (IGFBP) (responsible for IGF transport) and IGF receptors (responsible for IGF action). Growth hormone stimulates the production of IGF-1 in most tissues, including the cardiovascular system. Th e GH/IGF-1 axis regulates cardiac growth, stimulates myocardial contractility, and infl uences the vascular system.
Studies revealed confl icting results related to IGF-1 in AMI and heart failure [2] [3] [4] [5] . Th e Framingham and
Rotterdam studies, population-based assessments of cardiovascular risks, have reported that a low serum IGF-1 level was associated with heart failure 2, 3 . Th ere is an interesting question waiting for answer: does the GH/IGF-1 axis infl uence the outcome of AMI?
To address these issues, we investigated concentrations of IGF-1, GH, insulin, markers of insulin resistance and markers of infl ammation in AMI. We aimed to assess any possible association between serum GH/ IGF-1 axis following AMI and short-term survival rates.
Subjects and Methods

Subjects
A follow up clinical study was performed at the Department of Cardiology, Department of Intensive Care with Coronary Care Unit and Department of Cardiovascular Diseases, Tuzla University Clinical Center in Tuzla, during the period from January to December 2010. Th e study included 75 consecutive patients diagnosed with AMI (also analyzed for type and localization of AMI). Patient recruitment was based on the time of admission to the hospital. Inclusion criteria for the study group were age <80 years, AMI diagnosed by the World Health Organization criteria and blood sampling <24 h of symptom onset. Exclusion criteria were Killip class III or IV, body mass index (BMI) >30 kg/m 2 , acromegaly, Cushing syndrome, severe thyroid dysfunction, chronic infl ammatory diseases, pregnancy and women using estrogens, patients on glucocorticoid therapy, kidney failure (end stage) and liver dysfunction/failure. Two patients were excluded from the study according to exclusion criteria, so the analysis was performed on 73 AMI patients. Patients with AMI were followed-up for a six-month period (short-term prognosis). Most patients with AMI enrolled in the study (60 patients) were treated with primary percutaneous intervention (PCI), followed by conventional therapy (angiotensin converting enzyme (ACE) inhibitor, beta blocker, clopidogrel, acetylsalicylic acid and lipid lowering agents), whereas 13 patients were not treated with PCI (they received only the aforementioned drugs). We analyzed mortality and readmissions due to rest angina pectoris or reinfarction (new cardiac events) during the study period and examined left ventricular ejection fraction (LVEF).
Control group consisted of 30 healthy individuals presenting to the hospital for follow up check-ups (in this group, coronary disease was excluded by medical history, stress test, ultrasound and/or coronary angiography). Th e study and control groups were gender-and age-matched. Baseline characteristics of AMI patients and control subjects are shown in Table 1 . Five patients with previously diagnosed diabetes mellitus were on insulin therapy (biphasic insulin). Mild hypertension (grade II) was diagnosed in 40% of study group patients.
Th e study was approved by the local ethics committee, and all patients gave their written informed consent to participate in the study.
Methods
Blood samples were obtained and analyzed for the following hormones: growth hormone, IGF-1 and Complete blood count, enzymes of myocardial necrosis (troponin I, creatine kinase, creatine kinase myocardial fraction), electrolyte concentrations, glucose, urea, creatinine, uric acid, lipid profi le, glycolyzed hemoglobin (HbA1c) and liver function tests were carried out by the analytical unit of our Biochemistry Department by standard methods.
Th e homeostasis model of assessment-insulin resistance (HOMA-IR) was calculated using the international formula (fasting glucose mmol/L x fasting insulin mU/L/22.5) on a HOMA-IR Calculator version 2.2.
Echocardiography
Th e left ventricular ejection fraction (LVEF) was determined using Simpson's method (rule) on twodimensional Vivid 3 ultrasound. As stated above, we measured LVEF in AMI at baseline and six months later, and we tried to fi nd out if LVEF correlated with IGF-1 or GH. All AMI patients were divided into two groups: patients whose IGF-1 was below median and patients whose IGF-1 was above median. We analyzed if there was a signifi cant diff erence in LVEF between these two groups. Additionally, we investigated Values are presented as medians with lower and upper quartiles in brackets, followed by p-value according to Mann-Whitney analysis; PCI = percutaneous coronary intervention; IGF-1 = insulin-like growth factor 1; IGF1BP3 = insulin-like growth hormone 1 binding protein 3; GH = growth hormone; HOMA-IR = index of insulin resistance; HbA1c = glycolyzed hemoglobin; CRP = C-reactive protein; ns = nonsignifi cant mortality rate and the rate of readmissions due to reinfarction or rest angina pectoris during 180 days and tried to fi nd out if IGF-1 level at admission infl uenced these rates.
Statistical methods
Th e SPSS v.15 software (SPSS Inc., Chicago, Illinois, USA), Arcus Quick Stat and Microsoft Excel XP Professional were used on statistical analysis. Variables with asymmetric distribution were summarized as medians and interquartile ranges. Normality tests (ShapiroWilk) were used for all variables. On comparison of AMI patients and control subjects, continuous variables that were normally distributed were analyzed with twotailed t-test and unequally distributed variables were analyzed with Mann-Whitney U test. Categorical data and proportions were analyzed with the c 2 -test or Fisher exact test where appropriate. Regression and correlation analysis was also employed, as well as the receiver operator characteristic (ROC) analysis. A value of twosided p<0.05 was considered signifi cant.
Results
Th e control and study groups did not diff er according to age, gender and/or BMI. Shapiro Wilk test showed that variables were not normally distributed, so Mann-Whitney test was performed to analyze all study parameters except for IGF1BP-3. We found no statistically signifi cant diff erence between the study group and control group only when it came to insulin, although there was a strong tendency toward it. All other parameters evaluated showed statistically significant between-group diff erences.
Median values with lower and upper quartile, and p values are shown in Table 2 . Th ere were no statistically signifi cant diff erences in study parameters between the subgroups of AMI patients treated and not treated with PCI (Table 2) .
Simple linear correlation analysis showed positive linear correlation between GH and C-reactive protein (CRP) (r=0.350255; p=0.0158) and between IGF-1 and IGF1BP-3 (r=0.584808; p<0.0001). However, there was no linear correlation between GH and LVEF or between IGF-1 and LVEF.
Age, sex, BMI, prevalence of diabetes mellitus, hyperlipidemia, hypertension, smoking, obesity and Killip classifi cation were not diff erent between the patients with and without new cardiac events. Th e subgroup of patients treated with PCI did not have better outcome as compared with non-PCI patients (in fact, all patients with new cardiac events were in the PCI group). All patients with new cardiac events (fatal and nonfatal) had IGF-1 below median (IGF-1<123, range 82 to 159). Seven of eight patients had the GH level above median and IGF-1/GH ratio below median. During follow up period, all patients with new cardiac events had impaired fasting glucose or diabetes mellitus according to the American Diabetes Association criteria. It should be noted that all patients with new cardiac events were treated with PCI. Table 3 shows study parameters in patients with new fatal and nonfatal cardiac events. Figure 1 shows ROC analysis of parameters during follow up period in patients with and without new cardiac events. Table 4 shows the cut-off values of analyzed parameters with sensitivity, specifi city, positive and negative predictive values, and area under the curve (AUC). (Fig. 1, Table 4 ). We point out that cut-CRP = C-reactive protein; GH = growth hormone; HbA1c = glycolyzed hemoglobin; HOMA-IR = index of insulin resistance; IGF-1 = insulin-like growth factor 1 IGF-1 = insulin-like growth factor 1; GH = growth hormone; IGF1BP-3 = insulin-like growth factor 1 binding protein 3; CRP = C-reactive protein; HOMA-IR = index of insulin resistance off values of IGF-1 and GH represent medians of IGF-1 and GH in AMI at the same time. Figure 2 shows LVEF values in AMI patients with IGF-1 below median and IGF-1 above median during hospitalization and after six months. Patients with IGF-1 below median had a signifi cantly lower LVEF during hospitalization and after six months too (Fig. 2) .
Fig. 1. Receiver operating characteristic curve (ROC) analysis of study parameters during follow up period.
Discussion
In this study, the values of insulin resistant state (HOMA-IR) in the fi rst 24 hours following AMI were found to be higher in comparison with control group. Th e levels of fasting glucose concentration and HbA1c were also signifi cantly higher in the AMI group than in control group. Th ese results are similar to the results reported from some other recent studies [4] [5] [6] [7] [8] [9] [10] [11] [12] . A few well described mechanisms of hyperglycemia in AMI include insulin resistance, endothelial dysfunction, cortisol and cytokines. Baseline insulin levels showed no signifi cant diff erence between the study and control groups, which is also consistent with some other investigations, although HOMA-IR was higher in AMI, mostly because of higher glucose level (insulin was also higher, but the diff erence was not statistically signifi cant, so the fi nal product of insulin and glucose (HOMA-IR) showed a statistically signifi cant diff erence). In the aforementioned investigations, the authors also revealed insulin resistance without significant increase in baseline insulin 4, 8 . During follow up period, all patients with new cardiac events had at least impaired fasting glucose.
Previous studies have documented a decrease in IGF-1 levels following MI [4] [5] [6] . However, the role of GH/IGF-1 axis remains unclear [1] [2] [3] [4] . In the present study, the level of IGF-1 was lower and the level of GH higher in AMI patients than in controls (p<0.05 and p<0.001, respectively), and this fi nding is suggestive of GH resistance.
Th e IGF-1 might also be a good marker of patient outcome in AMI in the fi rst six months. We believe that in the future, IGF-1 could be routinely measured as an outcome marker in 180 days, although new investigations need to be done to confi rm this. As mentioned before, three patients died and fi ve patients had nonfatal cardiac events during follow up, so the total number of patients with both fatal and nonfatal cardiac events was eight. Th is number is small for clear predictive values and new researches need to be done, but we analyzed these patients as the topic is too interesting and important. For example, Yamaguchi et al. 6 had fi ve non-survivors during follow up period and they performed all analyses on that small sample.
As mentioned above, age, sex, BMI, prevalence of diabetes mellitus, hyperlipidemia, hypertension, smoking, obesity and Killip classifi cation were not diff erent between the patients with and without new cardiac events. Also, the subgroup of patients treated with PCI did not have better outcome than non-PCI group (in fact, all patients with new coronary events were in the PCI subgroup). All patients with fatal and nonfatal new cardiac events during follow up period had IGF-1 below median (<123; we pointed out above that patients with AMI were divided into two subgroups according to median). In other words, all cardiac mortality and other major new cardiac events were in the subgroup with IGF-1 below median, which is comparable to some other investigations 1, 6 in which AMI patients were analyzed during a 90-day period. However, in the aforementioned study by Yamaguchi et al. 6 , median of IGF-1 at admission was slightly higher than in our study (131 vs. 123 ng/mL), the authors followed-up patients over a shorter period then we did (90 vs. 180 days), and they did not measure and int=1.96 (p=0.028); t'=1.99 (p'=0.02) LVEF = left ventricular ejection fraction; IGF 1 = insulin-like growth factor 1; Xr' = mean value in patients at 6 months; t = t-test value during hospitalization; t' = t-test at 6 months; Xr = mean value during initial hospitalization; Xr' = mean value in patients at 6 months vestigate the relationship of GH, IGF-1/GH and IGF1BP-3. Moreover, our analyses showed that low IGF-1 level at admission might be a good prognostic marker at 180 days and not only at 90 days. We have to point out that we performed ROC analysis which showed low IGF1 (cut-off ≤123) and high GH (cutoff ≥0.96) to have high sensitivity 1 and AUC in predicting new cardiac events (123 and 0.96 are medians of IGF-1 and GH, respectively). On the contrary, IGF1BP-3, the main binding protein of IGF1, had low sensitivity but high specifi city, positive and negative predictive values 1 . Th e role of the above mentioned IGF1BP-3 is complex and still controversial, and there are confl icting results of IGF1BP-3 concentration in AMI. However, the actual role is not understood fully. A few authors found increased levels of IGF1BP-3 in AMI 13, 14 , whereas others report on decreased levels of IGF1BP-3 in AMI 15, 16 . In addition, we found positive linear correlation between IGF-1 and IGF1BP-3, as expected. Several additional aspects associated with the role of IGF-1 in AMI deserve consideration. Conti et al. 4 tried to explain the reasons for decreased level of IGF-1 and its binding protein IGF1BP-3 in AMI. Th ey discuss whether the level of IGF-1 is the cause of AMI or IGF-1 decreases secondarily in AMI, and they point out that IGF-1 also decreased secondarily due to immune/infl ammatory response which exerted IGF-1/GH axis and due to low IGF1BP-3. According to them, IGF1BP-3 could change plasma half-life of IGF-1 (plasma half-life of IGF-1 is 10 h; when IGF-1 is in complex with IGF1BP-3 it could be 20 h). In other words, low concentration of IGF1BP-3 means low level of IGF-1. According to our results, IGF1BP-3 level is not an independent predictor of new cardiac events in six-month period and it does not aff ect patient outcome signifi cantly but it is decreased in AMI and correlates with IGF-1.
All patients with new cardiac events (fatal and nonfatal) were stent treated, so the choice of therapy did not negatively interfere with the outcome of AMI. Seven of eight patients had the level of GH above median and IGF-1/GH ratio below median, so GH resistance appears to be linked to AMI outcome too. What is the possible explanation for this? Th e acute changes in GH concentration are supposed to be linked to the degree of the infl ammatory reaction and stress provoked by the infarction. We also found strong positive linear correlation between CRP and GH, and similar results have also been reported elsewhere 6 . It is well known that infl ammation plays an important role in the pathogenesis and course of acute coronary syndrome. Previous studies found elevated concentrations of nonspecifi c markers of infl ammation (CRP, fi brinogen) in the fi rst 24 hours of AMI [17] [18] [19] [20] [21] . We also found higher levels of CRP and fi brinogen in AMI. Above all, we found that all patients with new cardiac events had elevated values of CRP. CRP has also high sensitivity in predicting new cardiac events during 180-day period. We showed a strong positive correlation between infl ammation and IGF-1 axis. Additionally, there was no linear correlation between IGF-1 and markers of infl ammation or between GH/IGF-1 axis and markers of insulin resistance. Friberg et al. 5 found similar results as we did. Unlike this, Conti et al. 4 found decreased level of GH in AMI. We hypothesize that larger infarctions trigger a stronger infl ammatory response and activate the GH/IGF-1 axis. Th is could explain such confl icting fi ndings of GH levels in AMI. It therefore may be speculated that IGF-1/GH ratio (index of GH resistance) might be a useful prognostic marker in AMI (the lower the IGF1/GH ratio, the poorer is the outcome of AMI). Further investigations need to be done to confi rm this hypothesis.
Th e group of patients with IGF-1 below median had a signifi cantly lower LVEF during hospitalization and six months later, at follow up check-up. At follow up, LVEF was slightly better than in the fi rst days of AMI in both groups but diff erence between the two groups was obvious. Th is fi nding is of importance because Scharin Täng et al. 22 indicated an important role of circulating IGF-1 in preserving cardiac structure and function both in physiological settings and post myocardial infarction. Unlike Lee et al. 7 , we did not fi nd linear correlation between IGF-1 and LVEF. Despite this, we found a relationship between IGF-1 and LVEF without doubt, indicating that IGF-1 plays an important role in preserving cardiac function post myocardial infarction.
At the end, we want to point out that recently Bourron et al. 23 measured IGF-1 in 1005 patients with AMI. Th ey investigated whether IGF-1 at admission for AMI predicted death, all-cause death, recurrent AMI and stroke over a 2-year follow up. Th ey concluded that low IGF-1 score was associated with an increased risk of all-cause death, recurrent AMI and stroke in AMI patients. Th eir study was larger than ours and they followed-up patients longer than we did. But they did not measure IGF1BP-3, GH and insulinemia (as we did in our study), and therefore they could not exclude the role of GH (or IGF1 BP-3/insulin) in the higher risk of recurrent cardiovascular events observed in subjects with low IGF-1. Th e authors of this large study also said that these were potential limitations of their study. Our study was much smaller but we investigated precisely GH/IGF-1 axis and its link with insulinemia and infl ammation.
Our study limitations were single-center design and relatively small number of patients with new cardiac events during short-term follow up period, thus precluding any defi nite conclusions.
Conclusions
Th e main fi ndings of our study were lower IGF-1 and higher GH values in AMI as compared with control group. Besides low IGF-1/GH ratio, insulin resistance and elevated markers of infl ammation were found in the fi rst 24 hours of AMI. Strong linear positive correlation between CRP and GH might be the key of GH resistance state. Although further investigations are required, our results implicated that IGF-1 level might aff ect prognosis of AMI.
